JPM 2027: 6 Names That Move on Deals, Not Data

Everyone screens the data conferences. Fewer screen the deal conference, and that is the edge. ASCO moves oncology, ASH moves hematology, and the J.P. Morgan Healthcare Conference moves the deals. No abstracts, no late-breakers, no PDUFA readouts. It is balance sheets, cash runway, and patent-cliff-driven acquirer urgency. The 45th annual conference runs January 11 to 14, 2027 in San Francisco, and the trade fires in the first week of January, not at the podium.

Here is the rhythm. Big Pharma tips its M&A hand through late-December deal chatter, then formalizes it in the first week of January guidance and acquisition headlines. By the time management steps to the podium in San Francisco, the move has happened. The data-conference preview screens which abstracts re-rate a stock; this one screens which balance sheets do. The mechanics are in the JPM trading guide. Here are six names ranked by deal-flow potential, split into three groups.

Likely Acquisition Targets

1. Viking Therapeutics (VKTX) | $35.56 | Market Cap $4.15B | The obesity takeout magnet

Viking is the scarcest asset in biotech: an independent, late-stage obesity company. VK2735, a dual GLP-1/GIP agonist, is in Phase 3 in both subcutaneous and oral forms. VANQUISH-1 enrolled 4,650 patients with obesity, VANQUISH-2 enrolled roughly 1,000 with type 2 diabetes and obesity, and the oral program starts Phase 3 in Q4 2026. This is the second straight year Viking has topped the takeover target lists.

The signal to screen for is any Big Pharma obesity BD move between now and January. Lilly, Novo, Pfizer, and AstraZeneca all want the obesity market, and Viking is the one independent company with a late-stage oral-plus-injectable franchise. The re-rate thesis is a 50 to 100 percent buyout premium, which is why the risk is that the rumor premium is already baked in. At $4.15 billion, a deal is plausibly a $7 to $8 billion takeout. The read: the standalone data thesis and the takeout thesis converge here, which is rare.

2. Iovance Biotherapeutics (IOVA) | $11.00 | Market Cap $4.98B | Commercial TIL with a lung expansion

Iovance is the acquisition target with actual revenue. Amtagvi, the first FDA-approved tumor-infiltrating lymphocyte therapy, did $91 million in Q2 product revenue within $99.3 million total, at 56 percent gross margin, against full-year revenue guidance of $350 to $370 million. The company is under 5 percent penetrated into a 10,000 to 12,000 patient annual US melanoma market, and a non-small cell lung cancer BLA would roughly triple the addressable population.

The signal is an acquirer consolidating cell therapy manufacturing scale. The re-rate is the same bolt-on logic that drove Gilead’s Arcellx deal and argenx’s Forte pickup. The risk is that commercial TIL is capital-intensive, and any manufacturing failure-rate uptick compresses the margin story that just turned positive. The read: a takeover here is a nice-to-have, but the standalone commercial inflection is the real thesis.

3. Arrowhead Pharmaceuticals (ARWR) | $65.92 | Market Cap $9.28B | The RNAi platform target

Arrowhead is the RNAi pure play that RBC Capital Markets named among its top takeover targets this month. Plozasiran is filed for severe hypertriglyceridemia and advancing in FCS, competing directly with Ionis’s TRYNGOLZA. The plozasiran Phase 3 data gives the platform its first real approval shot. At $9.28 billion it sits above the sub-$5 billion digestible threshold, which means a deal would be a platform acquisition in the Vertex-Crinetics mold, not a bolt-on.

The signal is a large-cap paying up for RNAi, which Alnylam’s $34 billion valuation makes increasingly attractive to any acquirer who missed the platform. The risk is that $9.28 billion already prices the approval and the scarcity. The read: watch it, but the premium is thinner than on the names above.

Financing / IPO-Reopen Names

4. REGENXBIO (RGNX) | $7.40 | Market Cap $488M | Raise after the sura-vec readout

REGENXBIO is the textbook JPM financing story. It is pre-revenue, and the entire company rides on sura-vec, the AbbVie-partnered gene therapy for wet AMD, with Phase 3 topline data in Q4 2026. If the ATMOSPHERE and ASCENT wet AMD readout hits, REGENXBIO needs cash to push the BLA forward; if it misses, it needs cash to survive. Either way, a raise is coming, and JPM is where it gets telegraphed.

The signal is a pre-announced financing or an AbbVie restructuring of the deal terms. The re-rate thesis is that a strong readout plus a clean raise re-rates the stock from $488 million toward the several billion the wet AMD opportunity implies. The risk is that AbbVie holds the economics, leaving REGENXBIO with milestones and royalties that do not justify a large re-rate. The read: the Q4 data decides this one, and JPM is the tell.

5. Ultragenyx (RARE) | $14.50 | Market Cap $1.43B | Funding the Fayuvi launch

Ultragenyx enters 2027 in an unusual spot: it just won its first approval, Fayuvi for Sanfilippo syndrome type A, but the stock trades at $14.50 after the GTX-102 Angelman failure erased $1.2 billion of market cap in a day. The gene therapy catalyst picture now hinges on whether Ultragenyx can fund a commercial launch while advancing the rest of its pipeline.

The signal is a raise, a licensing deal, or guidance on how the Fayuvi launch is being financed. The re-rate thesis is that a successful launch removes the funding overhang and lets the market value the platform again. The risk is that the launch is slow and the raise is dilutive. The read: JPM is where Ultragenyx either repairs its balance sheet story or confirms the market’s worst case.

2027 Guidance-Setters

6. Ionis (IONS) | $44.50 | Market Cap $7.4B | Front-running 2027 on two wins

Ionis is the mid-cap that uses JPM to front-run guidance. It enters 2027 with two fresh wins: zilganersen approved September 3 as ZANVASTRO for Alexander disease, and ulefnersen’s Phase 3 FUSION win in FUS-ALS on September 22. The signal to screen for is 2027 revenue guidance plus the ulefnersen regulatory timeline, which Otsuka will push toward a filing.

The re-rate thesis is that the antisense platform’s third approval in a year closes the valuation gap with Alnylam. The risk is that Ionis’s commercial execution has historically lagged its science. The read: Ionis is the one guidance name where a January pre-announcement can actually move the stock, because the market has not yet priced the ulefnersen filing into a $7.4 billion valuation.

The Mega-Cap Filter

Pfizer, Merck, Bristol Myers, Lilly, Novo, and AstraZeneca will dominate the JPM headlines and move zero basis points on a routine presentation. A $100 billion-plus company showing a slide deck does not re-rate. These names matter here only as the acquirer side of a target thesis, which is why the patent-cliff M&A targets screen is the frame, not the presenter list.

The Deal-Consumed Caveat

Some targets get bought before JPM, which is the catalyst-consumed lesson from the data-conference side. The Telix-ITM radiopharma merger, Lilly’s Merida and AtaiBeckley pickups, argenx’s Forte deal, and Vertex’s Crinetics acquisition all removed names from the 2027 board before this preview was written. Verify every name is still independent and listed before you position in December, and cross-check against the August financing wave for who already raised.

The Playbook

The conference trading playbook applies, with a deal twist. Position by the first week of January, not during the conference. Size any rumor trade at 1 to 2 percent, as speculation, not thesis. Sell the January pop instead of holding into the February fade. The Monday-opening M&A window is where announced deals land; the rumor run-up before it is where most of the money is already gone.

The verdict: Viking and Ionis are the two names that actually re-rate. Viking carries the cleanest takeout thesis in biotech, and Ionis carries the cleanest guidance catalyst on a valuation that has not caught up to the pipeline. Iovance and RGNX are the second tier, each with a real catalyst but a financing or manufacturing question attached. Arrowhead and Ultragenyx are watch-list names. Position in December, screen for the deal signal, and treat the rumor as the exit, not the entry.